REG - Trellus Health PLC - Business update

Trellus HealthAnnouncement

03/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260203:nRSC3715Ra&default-theme=true

RNS Number : 3715R  Trellus Health PLC  03 February 2026

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Business update

 

LONDON, U.K. AND NEW YORK, U.S. (3 February 2026). Trellus Health plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programmes and value-based solutions to manage complex chronic
conditions, provides the following business update.

 

Operational and Commercial Progress

Since the Company's interim results for the six months ended 30 June 2025,
Trellus Health has continued to make progress across its core strategic
verticals, with particular momentum in the clinical trials sector.

 

Clinical Trials Vertical

 

·   In October 2025, the Company entered into a 12-month contract
with ICON plc, a global contract research organisation ("CRO"), to support
recruitment and enrolment optimisation for an ongoing mid-stage immunology and
inflammation clinical trial sponsored by Takeda. The contract includes an
upfront fee, monthly management fees and milestone-based payments linked to
defined performance indicators.

The Company has begun launching the program into agreed-upon sites.

·    Later in October 2025, the Company entered into a second 12-month
commercial contract with PSI Inc., another global CRO, to deploy its Trellus
TrialSet™ solution across two late-stage immunology and inflammation
clinical trials sponsored by Sanofi. This represents the Company's second
commercial CRO contract following the launch of TrialSet™. The Company is
implementing the programme now and expects to be fully launched in mid-Q1.

·    In addition, Trellus Health® continues to support an ongoing Phase
2 IBD clinical trial pursuant to its licensing agreement with AstraZeneca.

·    The Company has been granted preferred vendor status by both ICON plc
and PSI Inc., which is expected to facilitate access to pharmaceutical
sponsors and streamline future contracting processes.

 

Pharmaceutical and Patient Support Programmes

·     The collaboration with Johnson & Johnson Health Care Systems
Inc., signed in January 2025, continues to progress. During the pilot phase,
engagement and satisfaction metrics were achieved, and in mid-January 2026
enrolment channels were broadened beyond the initial pilot funnel.

·     In the second quarter of 2025, the Company renewed its agreement
with Pfizer to license patient support educational content for inclusion in
Pfizer's IBD digital application. Discussions are ongoing regarding a
potential expansion with the expected renewal in 2026.

Platform and Product Development

· The Company continues to expand Trellus TrialSet™ as a
condition-agnostic solution, extending its applicability beyond IBD into
additional therapeutic areas.

·   Ongoing enhancements to the Trellus Elevate® platform and user
experience have supported engagement across active programmes.

·  Work to achieve GDPR compliance is underway, alongside continued
maintenance of the Company's SOC 2 Type II certification.

 

Funding and Outlook

The Company expects revenue for the year ended 2025 to be c. $545,000. As
previously disclosed, the Company has further reduced its monthly cash burn to
approximately $400,000, which was moderately offset by recurring monthly
management fees generated during the second half of the year.

As announced previously, the Company has secured a £5 million convertible
facility with Alumni Capital LLC, which was approved by shareholders on 20
January 2026. The Company believes that the net proceeds of the First Tranche
Notes and Second Tranche Notes, which together total £737,500 in gross
principal, will extend the Company's cash runway into late Q1 2026. The
Directors remain in ongoing discussions regarding alternative sources of
additional funding to further extend the Company's cash runway, irrespective
of the utilisation of the Notes

The Board is focused on driving commercial momentum and expanding the
Company's footprint through strategic partnerships, particularly within
pharmaceutical and clinical trial verticals and has been very encouraged by
the increasing validation of the Company's resilience-based methodology.

 

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said, "We are
very pleased with the progress across our verticals during the second half of
the year. Whilst reducing our monthly burn by c. 23% since the beginning of
2025, we successfully executed our patient support programme with J&J and
developed and launched TrialSet™. We are now implementing TrialSet™ with
our CRO partners and have commenced work with participating individual
clinical sites."

"We continue to manage costs and working capital carefully and are encouraged
by the growing validation of our differentiated, behavioural science-based
approach. We remain focused on progressing commercial discussions and look
forward to updating the market on further developments."

 

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Phil Davies / James Todd / Patrick Weaver                             Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

 

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation. Both the
founders continue to have a financial interest in the Company.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSSEFLEEMSELE



            Copyright 2019 Regulatory News Service, all rights reserved